JP2005525352A5 - - Google Patents

Download PDF

Info

Publication number
JP2005525352A5
JP2005525352A5 JP2003570776A JP2003570776A JP2005525352A5 JP 2005525352 A5 JP2005525352 A5 JP 2005525352A5 JP 2003570776 A JP2003570776 A JP 2003570776A JP 2003570776 A JP2003570776 A JP 2003570776A JP 2005525352 A5 JP2005525352 A5 JP 2005525352A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
vegfr
composition according
inhibitor
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003570776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525352A (ja
Filing date
Publication date
Priority claimed from US10/081,126 external-priority patent/US20030180294A1/en
Application filed filed Critical
Publication of JP2005525352A publication Critical patent/JP2005525352A/ja
Publication of JP2005525352A5 publication Critical patent/JP2005525352A5/ja
Pending legal-status Critical Current

Links

JP2003570776A 2002-02-22 2003-02-20 角膜移植片の生存を延長させる方法 Pending JP2005525352A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/081,126 US20030180294A1 (en) 2002-02-22 2002-02-22 Methods of extending corneal graft survival
PCT/US2003/005125 WO2003072029A2 (en) 2002-02-22 2003-02-20 Methods of extending corneal graft survival

Publications (2)

Publication Number Publication Date
JP2005525352A JP2005525352A (ja) 2005-08-25
JP2005525352A5 true JP2005525352A5 (https=) 2006-04-06

Family

ID=27765253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003570776A Pending JP2005525352A (ja) 2002-02-22 2003-02-20 角膜移植片の生存を延長させる方法

Country Status (6)

Country Link
US (1) US20030180294A1 (https=)
EP (1) EP1476187A4 (https=)
JP (1) JP2005525352A (https=)
AU (1) AU2003215337B2 (https=)
CA (1) CA2476994A1 (https=)
WO (1) WO2003072029A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
KR100402497B1 (ko) * 2000-11-30 2003-10-22 주식회사 엘지이아이 전자레인지의 가열장치
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CA2435503C (en) * 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6709655B2 (en) * 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
CN1555488A (zh) * 2001-07-12 2004-12-15 路德维格癌症研究院 淋巴管内皮细胞物质及方法
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
CA2519835A1 (en) * 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection
EP1635860A2 (en) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d in reconstructive surgery
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
EP1651266B1 (en) * 2003-07-25 2010-03-03 Laboratorios Silanes, S.A. de C.V. Administration of anti-tnf-alpha f(ab')2 antibody fragments
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
US20080070855A1 (en) * 2006-09-20 2008-03-20 James Pitzer Gills Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
KR20160021307A (ko) 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
JP6105838B2 (ja) * 2010-08-24 2017-03-29 国立大学法人 岡山大学 疼痛の治療剤
US9364535B2 (en) * 2012-08-15 2016-06-14 The Regents Of The University Of California Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
JP2020503255A (ja) * 2016-10-27 2020-01-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンアルファ９の遮断はリンパ弁形成を抑制し、移植片の生存を促進する
CN119055769B (zh) * 2023-08-17 2025-09-05 南方医科大学南方医院 抗血管生成药物在提高软组织移植物保留率中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
EP1339438B1 (en) * 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
DE10134196B4 (de) * 2001-07-13 2005-08-18 Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen

Similar Documents

Publication Publication Date Title
JP2005525352A5 (https=)
Seferian et al. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?
Bonegio et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy
Huang et al. Upregulation of angiotensin‐converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors
CN110536683A (zh) 包含PPAR激动剂如伊拉非诺和乙酰CoA羧化酶ACC抑制剂的组合
JP2023533447A (ja) がんを処置する併用療法
HRP20030460A2 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
US20190022225A1 (en) Protocol for increasing life expectancy in a test subject
KR20040093058A (ko) Ｎ-(5-(4-(4-메틸-피페라지노-메틸)-벤조일아미도-2-메틸페닐)-4-(3-피리딜)-2-피리미딘-아민 코팅된 스텐트
BR0207321A (pt) Implantes com fk506
JP2022533578A5 (https=)
ATE504288T1 (de) Oros-push-stick für die kontrollierte abgabe von wirkstoffen
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
AU2011322597B2 (en) Dosing regimes for the treatment of ocular vascular disease
BRPI0714815A2 (pt) composiÇço, e, uso de um (a) agonista e (b) um agente anti-infeccioso
JP2007502327A5 (https=)
CN111343980A (zh) 右美沙芬经皮递送装置
Palmes et al. Impact of rapamycin on liver regeneration
JP2004527469A5 (https=)
US20160151406A1 (en) Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides
Gabra et al. Absence of diabetic hyperalgesia in bradykinin B1 receptor-knockout mice
EP1152002A4 (en) PYRROL DERIVATIVES AND CELL DEATH INHIBITORS
EP2029139A1 (en) Use of a p38 kinase inhibitor for treating psychiatric disorders
EP3804724B1 (en) Cdk inhibitors for treating pah
Casserly et al. C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade